Informational only — Not medical advice. Always consult a licensed healthcare provider.

Shasthya স্বাস্থ্য · Health, made simple
বাং
Community data Updated 22 hours ago
🌐 বাংলায় দেখুন

Indications

Bendamustine is indicated for the treatment of patients with chronic lymphocytic leukemia (CLL). Its efficacy compared with first line therapies other than chlorambucil has not been established. In non-Hodgkin lymphoma (NHL), Bendamaxis is indicated for indolent B-cell non-Hodgkin lymphoma that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Bendamustine is also indicated in multiple myeloma.

⚠️ Always consult a registered physician before taking any medicine.

Pharmacology

Bendamustine is a derivative of mechlorethamine with two reactive arms, and it can form electrophilic alkyl groups that bond covalently to other molecules. It works as an alkylating agent. In this way it creates intra- and inter-strand crosslinks between DNA bases, and this leads to cell death. Bendamustine is active against both active and quiescent cells, though the exact mechanism of action is not known.

Pregnancy & Breastfeeding

Bendamustine is in pregnancy category D. This means there is positive evidence of risk to the human fetus. Even so, the benefit of using it in a pregnant woman may be acceptable despite that risk, for example when the medicine is needed in a life-threatening situation, or for a serious disease where safer drugs can't be used or don't work.

⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.

Dosage Reference

⚠️ Reference ranges from official sources only. Consult your doctor for personalized dosing.

Adults: For chronic lymphocytic leukaemia, the bendamustine dose is 100 mg/m2, infused over 30 to 60 min on days 1 and 2 of a 28-day cycle, for up to 6 cycles. If severe haematological or non-haematological toxicity occurs, the dose is reduced to 50 mg/m2 on days 1 and 2 of each cycle. If severe haematological toxicity recurs, it is reduced further to 25 mg/m2 on days 1 and 2 of each cycle. Raising the dose again in later cycles may be considered. For multiple myeloma, the dose is 120 to 150 mg/m2, infused over 30 to 60 min on days 1 and 2 of a 28-day cycle. Prednisone, given either IV or by mouth, may be added at 60 mg/m2 on days 1 to 4 of the cycle. For Non-Hodgkin's lymphoma, bendamustine is given at 120 mg/m2, infused over 30 to 60 min on days 1 and 2 of a 21-day cycle, for up to 8 cycles. If severe haematological or non-haematological toxicity occurs, the dose is reduced to 90 mg/m2 on days 1 and 2 of each cycle. If severe toxicity recurs, it is reduced further to 60 mg/m2 on days 1 and 2 of each cycle.

Side Effects & Interactions

Side Effects

No side-effect data recorded yet.